Evidence map›Paper›PMID 40360880›Full record

ArticleLeukemia2025

Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Dennis A Eichenauer, Aylin Basaran, Ina Bühnen, Michael Fuchs, Bastian von Tresckow, Andreas Rosenwald, Martin-Leo Hansmann, Heinz-Wolfram Bernd, Peter Borchmann, Wolfram Klapper and 1 more

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Diagnosis of classic Hodgkin lymphoma and its imitators].Pathologie (Heidelberg, Germany) · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dennis A EichenauerUniversity of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany. dennis.eichenauer@uk-koeln.de.ORCID 0000-0002-1927-3514
Aylin BasaranUniversity of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
Ina BühnenUniversity of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
Michael FuchsUniversity of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.ORCID 0000-0003-3289-3272
Bastian von TresckowGerman Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.ORCID 0000-0003-1410-4487
Andreas RosenwaldInstitute of Pathology, University of Würzburg and Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany.
Martin-Leo HansmannInstitute of Pathology and Molecular Pathology, Helios University Hospital Wuppertal, Wuppertal, Germany.
Heinz-Wolfram BerndHematopathology Lübeck, Lübeck, Germany.
Peter BorchmannUniversity of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
Wolfram KlapperInstitute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.ORCID 0000-0001-7208-4117
Sylvia HartmannInstitute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0003-3424-1091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histopathological growth patterns (GP) in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) have previously been divided into GP AB (typical) vs CDEF (variant). However, it is unclear whether this division is optimal. We thus investigated alternative GP grouping approaches (GP ABC vs DEF; GP ABCF vs DE). Overall, 583 NLPHL patients who had first-line treatment within GHSG trials were included in the analysis. Median age was 39 years; 74% of patients were male; 76% presented with early-stage and 24% with advanced-stage disease. The 5-year and 10-year progression-free survival (PFS) estimates for all patients were 85.9% and 76.6%; overall survival (OS) estimates were 95.8% and 94.5%. Significant PFS and OS differences were detected for the comparison GP ABCF vs DE with worse outcomes for the GP DE group (HR: 1.7; 95%-CI: 1.1-2.7; HR: 2.5; 95%-CI: 1.1-5.7). No PFS and OS differences were observed for the comparisons GP AB vs CDEF and GP ABC vs DEF. Median time to death was shorter and death more often due to NLPHL in the GP DE (13 months; 66.7%) than in the GP ABCF (31 months; 5.6%) group. Hence, the division of GP into GP ABCF vs DE allows an optimized GP-based risk group discrimination in NLPHL.

Indexed as

Hodgkin DiseaseLymphocytesAdolescentAdultAgedFemaleFollow-Up StudiesGermanyHumansMaleMiddle AgedNeoplasm StagingPrognosisSurvival RateYoung Adult

Identifiers

PMID40360880
PMCPMC12208872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.